Ten projects have been awarded funding within the JPIAMR 6th transnational call: “Innovations against antibiotic-resistant bacteria: New targets, compounds and tools”. The total funding amount is 12,8 M€.
The call was launched in January 2018 and supported by 16 research-funding organisations from JPIAMR member countries. The primary aim of the call is to combine the resources, infrastructures, and research strengths of multiple countries in order to address the identification and validation of new targets, the development of new therapies, and new tools for new treatments (including new antibiotics).
104 applications were received, involving 468 partners. The evaluation process included international experts that performed remote evaluation and constituted the peer review panel. In total ten transnational projects were granted funding.
For any questions concerning the call results, please contact the Joint Call Secretariat:
Agence Nationale de la Recherche
Phone: +33 (0)1 78 09 80 44
The projects awarded funding within the call are:
|ANTIBIO-LAB||Anti-Biofilm therapies using Local Application of bacteriophages||Fintan Moriarty||AO Research Institute Davos||Belgium, Switzerland, Germany|
|Anti-Persistence||Fighting antibiotic-resistant superbugs with anti-persister compounds targeting the stringent response||Abel Garcia-Pino||Université Libre de Bruxelles||Belgium, France, Spain, Poland|
|CRISPRattacK||Advancing CRISPR antimicrobials to combat the bacterial pathogen Klebsiella pneumoniae||Chase Beisel||Helmholtz Center for Infection Research||Israël, France, Germany|
|DISRUPT||Fighting antimicrobial resistant infections by high-throughput discovery of biofilm-disrupting agents and mechanisms||Morten Kjos||Norwegian University of Life Sciences||Norway, Germany, Switzerland|
|Explore||Exploration of the TPP riboswitch as a new target for antibiotics||Ruth Brenk||University of Bergen||Canada, Czech Republic, Latvia, Germany, Norway|
|FLAV4AMR||Flavodoxin inhibitors to kill resistant bacteria||Javier Sancho||University of Zaragoza||France, Germany, Spain|
|MTI4MDR-TB||Development of novel Mycobacterial Tolerance Inhibitors (MTIs) against MDR/XDR tuberculosis||Fredrik Almqvist||Umeå University||France, Norway, Spain, Sweden, USA|
|RESET-ME||Restoring E. coli Sensitivity for Antibiotics by blocking TolC-Mediated Efflux||Björn Windshügel||Fraunhofer Institute for Molecular Biology and Applied Ecology IME||Finland, Germany, Italy, Latvia,|
|RIBOTARGET||Development of Novel Ribosome-targeting Antibiotics||Daniel Wilson||University of Hamburg||Germany, Czech Republic, France, Sweden, Switzerland, Italy|
|SCAN||Design, Synthesis and Lead Generation of Novel Siderophore Conjugates for the Detection and Treatment of Infections by Gram-Negative Pathogens||Mark Brönstrup||Helmholtz Centre for Infection Research||France, Germany, Israël|